Health ❯Pharmaceuticals ❯Drug Approval

FDA Regulations

AstraZeneca Compounding Pharmacies Safety Testing Rare Disease Treatments

GLP-1 Agonists Tied to Higher Risk of Macular Degeneration and Rare Optic Neuropathy

Regulators have updated semaglutide product information to include optic neuropathy as a very rare side effect following new studies on vision risks.

Regulators Intensify Warnings on Unregulated Nasal Tanning Sprays Over Health Risks

FDA Approves First At-Home Nasal Spray Flu Vaccine